BioCentury | Nov 10, 2014
Clinical News

NKTT120 regulatory update

...for the indication, for which the product also has Orphan Drug designation in the U.S. NKT Therapeutics Inc....
BioCentury | Jan 13, 2014
Clinical News

NKTT120: Interim Phase I data

...II trials with NKTT120 are planned after the optimal dose of the compound is determined. NKT Therapeutics Inc....
BioCentury | Oct 11, 2010
Company News

NKT Therapeutics management update

NKT Therapeutics Inc. , Waltham, Mass. Business: Inflammation, Cancer, Autoimmune Hired: Barbara Finck as CMO, formerly SVP of R&D and CMO at Osprey Pharmaceuticals U.S.A. Inc. WIR Staff...
BioCentury | Jun 10, 2010
Distillery Techniques

Technology: Drug platforms

...steps include identifying other serum proteins with NK cell-stimulating activity. Wittycell S.A.S., Cytheris S.A. and NKT Therapeutics Inc....
BioCentury | Jan 25, 2010
Finance

SVLS closes V fund

...technology company Juvaris BioTherapeutics Inc. , respiratory company Mpex Pharmaceuticals Inc. , immune modulator company NKT Therapeutics Inc....
BioCentury | Oct 26, 2009
Company News

NKT Therapeutics, Kyowa Hakko Kirin deal

...upfront payment and is eligible for development milestones and royalties. Further terms were not disclosed. NKT Therapeutics Inc....
BioCentury | Apr 6, 2009
Company News

NKT Therapeutics board of directors update

NKT Therapeutics Inc. , Newton, Mass. Business: Inflammation, Cancer, Autoimmune Appointed: Michael Ross, managing partner at SV Life Sciences; and Joseph Amprey, senior managing director of MedImmune Ventures WIR Staff...
Items per page:
1 - 7 of 7
BioCentury | Nov 10, 2014
Clinical News

NKTT120 regulatory update

...for the indication, for which the product also has Orphan Drug designation in the U.S. NKT Therapeutics Inc....
BioCentury | Jan 13, 2014
Clinical News

NKTT120: Interim Phase I data

...II trials with NKTT120 are planned after the optimal dose of the compound is determined. NKT Therapeutics Inc....
BioCentury | Oct 11, 2010
Company News

NKT Therapeutics management update

NKT Therapeutics Inc. , Waltham, Mass. Business: Inflammation, Cancer, Autoimmune Hired: Barbara Finck as CMO, formerly SVP of R&D and CMO at Osprey Pharmaceuticals U.S.A. Inc. WIR Staff...
BioCentury | Jun 10, 2010
Distillery Techniques

Technology: Drug platforms

...steps include identifying other serum proteins with NK cell-stimulating activity. Wittycell S.A.S., Cytheris S.A. and NKT Therapeutics Inc....
BioCentury | Jan 25, 2010
Finance

SVLS closes V fund

...technology company Juvaris BioTherapeutics Inc. , respiratory company Mpex Pharmaceuticals Inc. , immune modulator company NKT Therapeutics Inc....
BioCentury | Oct 26, 2009
Company News

NKT Therapeutics, Kyowa Hakko Kirin deal

...upfront payment and is eligible for development milestones and royalties. Further terms were not disclosed. NKT Therapeutics Inc....
BioCentury | Apr 6, 2009
Company News

NKT Therapeutics board of directors update

NKT Therapeutics Inc. , Newton, Mass. Business: Inflammation, Cancer, Autoimmune Appointed: Michael Ross, managing partner at SV Life Sciences; and Joseph Amprey, senior managing director of MedImmune Ventures WIR Staff...
Items per page:
1 - 7 of 7